Latest Breaking News On - Hangzhou zhongmei huadong pharmaceutical co - Page 1 : vimarsana.com

MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzo

  COPENHAGEN, Denmark and HANGZHOU, China, August 31, 2023 / B3C newswire / MC2 Therapeutics, Ltd (“MC2”), a wholly owned subsidiary of MC2 Therapeutics A/S and Hangzhou Zhongmei Huadong Pharmaceutical Co (“Huadong”), a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), announced today a.

Liang luHong kongJesperj langeBo chenHuadong medicine co ltdTherapeutics ltdHangzhou zhongmei huadong pharmaceutical coGreater chinaChief executive officerHuadong medicinePatient centeredScience driven

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit tiered royalties WESTLAKE VILLAGE, Calif. and HANGZHOU, China, Aug. 10, 2023 (GLOBE NEWSWIRE) Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huad

Hong kongRepublic ofUnited statesLiang luFrank watanabeAmanda sheldonHuadong medicine co ltdDrug administrationArcutis biotherapeutics incExchange commissionHangzhou zhongmei huadong pharmaceutical coHead of corporate communicationsGreater chinaSoutheast asiaChief executive officerHuadong medicine

Arcutis Biotherapeutic (ARQT) and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

Arcutis Biotherapeutic (ARQT) and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongRepublic ofUnited statesLiang luFrank watanabeHangzhou zhongmei huadong pharmaceutical coArcutis biotherapeutics incHuadong medicine co ltdGreater chinaSoutheast asiaChief executive officer

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLiang luRepublic ofHong kongMediaamanda sheldonFrank watanabeInvestorseric mcintyreHuadong medicine co ltdArcutisarcutis biotherapeutics incDrug administrationHangzhou zhongmei huadong pharmaceutical coExchange commissionArcutis biotherapeutics incHead of corporate communicationsGreater chinaSoutheast asia

Arcutis and Huadong Announce Strategic Collaboration and

Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit.

United statesHong kongRepublic ofLiang luAmanda sheldonFrank watanabeHuadong medicine co ltdHangzhou zhongmei huadong pharmaceutical coArcutis biotherapeutics incDrug administrationExchange commissionHead of corporate communicationsGreater chinaSoutheast asiaChief executive officerHuadong medicine